Italia markets open in 5 hours 25 minutes

AbbVie Inc. (0QCV.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
146,95-0,42 (-0,28%)
Alla chiusura: 07:14PM BST
Schermo intero
Chiusura precedente147,37
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno146,93 - 147,40
Intervallo di 52 settimane146,93 - 147,40
Media VolumeN/D
Beta (5 anni mensile)0,55
Rapporto PE (ttm)0,21
EPS (ttm)6,97
Prossima data utili26 ott 2023 - 30 ott 2023
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease

    Data readout expected in Q4 2024SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Data from the trial are expected in the fourth quarter of 2024. AL00

  • GlobeNewswire

    Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

    SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee. “Kim and Scott’s extensive strategic, financial and clinical expertis

  • GlobeNewswire

    Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields

    VANCOUVER, British Columbia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the termination of the Rodan + Fields (R+F) agreement for supply and use of TFC-1067 in commercial formulations. Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will now be the sole licensee of the technology as per the agreement signed June 2022. About Sirona Biochem Corp.Sirona Biochem is a cosmetic ingredient and drug discovery company with a propr